Bristol Myers Squibb Reports Phase 3 KarMMa-3 Results for Abecma in Multiple Myeloma

Bristol Myers Squibb today announced results from the Phase 3 KarMMa-3 trial evaluating Abecma (idecabtagene vicleucel) versus standard regimens in patients with relapsed or refractory multiple myeloma who had received two to four prior lines of therapy. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with Abecma.